Gemphire Therapeutics – $30 Million IPO

San Diego – August 22, 2016 – Cooley advised the underwriters on Gemphire Therapeutics Inc.'s $30 million initial public offering. The company's common stock now trades on The NASDAQ Global Market under the symbol "GEMP."

Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. Canaccord Genuity acted as co-lead manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital acted as co-managers.

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and nonalcoholic fatty liver disease.

The Cooley corporate and securities team advising the underwriters included Div Gupta, Charlie Kim, Nicole Brookshire, Siana Lowrey, Kristin VanderPas, Jonie Kondracki, Susan Walker and Adrienne Directo.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta  Partner New York
Charlie Kim  Partner San Diego, Los Angeles – Santa Monica
Natasha Leskovsek  Of Counsel Washington, DC
Kevin King  Partner Washington, DC
Bill Christiansen  Partner Seattle
Phil Mitchell  Partner New York
Siana Lowrey  Partner San Francisco
Kristin VanderPas  Partner San Francisco
Jonie Ing Kondracki  Partner San Francisco
Karen Tsai  Special Counsel Washington, DC